Literature DB >> 32297384

Safety of double-balloon enteroscopy in postoperative pediatric patients.

Kohei Matsushita1, Mikihiro Inoue1, Yuka Nagano1, Yuhki Koike1, Kohei Otake1, Yoshiki Okita1, Keiichi Uchida1, Masato Kusunoki1.   

Abstract

BACKGROUND: The aim of the present study was to investigate the efficacy and safety of double-balloon enteroscopy (DBE) in postoperative pediatric patients.
METHODS: This was a retrospective analysis of pediatric patients 18 years and younger referred to Mie University Hospital. Twenty procedures in 11 children occurred postoperatively; 29 children (42 procedures) had not undergone surgery.
RESULTS: Among postoperative patients, five DBE procedures were performed via the oral route, 12 via the anal route, and three via a stomal route. Among nonoperative patients, 14 DBE procedures were performed via the oral route and 28 via the anal route. Four postoperative patients and two nonoperative patients had difficult pleating via the transanal route because of adhesions or thickening of the intestinal wall resulting from inflammation (P = 0.02). Excluding patients with stenosis, the mean length of endoscopic insertion for transanal procedures was significantly shorter among postoperative patients than among nonoperative patients (73.6 cm vs 160.5 cm, P < 0.01). There were no major complications in either group.
CONCLUSIONS: Insertion difficulty was encountered in postoperative pediatric patients. However, our findings indicate that DBE is a safe procedure in postoperative pediatric patients.
© 2020 Japan Pediatric Society.

Entities:  

Keywords:  complication; double-balloon enteroscopy; pediatric; postoperative procedure

Mesh:

Year:  2020        PMID: 32297384     DOI: 10.1111/ped.14249

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  1 in total

1.  Diagnostic value of capsule endoscopy and double-balloon enteroscopy in small bowel diseases.

Authors:  Lijuan Qian; Yijie Gu; Lu Zheng; Tingting Xia
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.